Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GENEr8-AAV5+ study of valoctocogene roxaparvovec in Hemophilia A
NCT03520712Phase 2Terminated
- Sponsor
- BioMarin Pharmaceutical
- Start
- Apr 2018
- Primary completion
- Aug 2024
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 4
01
Overview
A Phase 2 trial of valoctocogene roxaparvovec in hemophilia A, sponsored by BioMarin Pharmaceutical. Started Apr 2018; status: terminated.
02
Drugs
valoctocogene roxaparvovec
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT03520712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03520712.